Personalized dosimetry of 131I-rituximab radioimmunotherapy of lymphoma

被引：0
|
作者：
Boucek, J. A. [1 ]
Turner, J. [1 ]
机构：
[1] Univ Western Australia, Fremantle Hosp, Fremantle, WA, Australia
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2009年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S261 / S262
页数：2
相关论文
共 50 条
  • [21] Repeated radioimmunotherapy with 131I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma
    Kang, Hye Jin
    Lee, Seung-Sook
    Byun, Byung Hyun
    Kim, Kyeong Min
    Lim, Ilhan
    Choi, Chang Woon
    Suh, Cheolwon
    Kim, Won Seog
    Nam, Seung-Hyun
    Lee, Soon Il
    Eom, Hyeon Seok
    Shin, Dong-Yeop
    Lim, Sang Moo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (04) : 945 - 953
  • [22] Repeated radioimmunotherapy with 131I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma
    Hye Jin Kang
    Seung-Sook Lee
    Byung Hyun Byun
    Kyeong Min Kim
    Ilhan Lim
    Chang Woon Choi
    Cheolwon Suh
    Won Seog Kim
    Seung-Hyun Nam
    Soon Il Lee
    Hyeon Seok Eom
    Dong-Yeop Shin
    Sang Moo Lim
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 945 - 953
  • [23] Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin's lymphoma:: initial experience
    Bienert, M
    Reisinger, I
    Srock, S
    Humplik, BI
    Reim, C
    Kroessin, T
    Avril, N
    Pezzutto, A
    Munz, DL
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 (10) : 1225 - 1233
  • [24] Radioimmunotherapy for indolent non Hodgkin lymphoma with 131I-rituximab in clinical practice:: 8 year single institution experience of 129 consecutive patients
    Leahy, M. F.
    Turner, J. H.
    ANNALS OF ONCOLOGY, 2008, 19 : 87 - 87
  • [25] A Phase II Study of 131I-rituximab for Patients With Relapsed or Refractory Marginal Zone Lymphoma
    Jang, Yoon Jung
    Lim, Sang Moo
    Lee, Inki
    Byun, Byung Hyun
    Lim, Ilhan
    Kim, Byung Il
    Choi, Chang Woon
    Lee, Seung-Sook
    Yang, Sung Hyun
    Na, Im Il
    Lee, Hyo-Rak
    Shin, Dong-Yeop
    Kang, Hye Jin
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2023, 17
  • [26] Clinical scale preparation and evaluation of 131I-Rituximab for Non-Hodgkin's Lymphoma
    Kameswaran, Mythili
    Vimalnath, K. Viswanathan
    Rajeswari, Ardhi
    Joshi, Prahlad Vasudeo
    Sarma, H. D.
    Samuel, Grace
    RADIOCHIMICA ACTA, 2014, 102 (06) : 553 - 560
  • [27] Radioimmunotherapy with 131I-Rituximab in a Patient with Diffuse Large B-Cell Lymphoma Relapsed After Treatment with 90Y-Ibritumomab Tiuxetan
    Kang G.W.
    Kang H.J.
    Shin D.-Y.
    Gu H.R.
    Choi H.S.
    Lim S.M.
    Nuclear Medicine and Molecular Imaging, 2013, 47 (4) : 281 - 284
  • [28] SUVmax predicts survival in patients with diffuse large B-cell lymphoma who received radioimmunotherapy using 131I-rituximab as consolidation therapy
    Choi, J.
    Lim, I.
    Byun, B.
    Kim, B.
    Choi, C.
    Lim, S.
    Shin, D.
    Kang, H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S777 - S778
  • [29] 131I-rituximab:: Relationship between immunoreactivity and specific activity
    Schaffland, AO
    Buchegger, F
    Kosinski, M
    Antonescu, C
    Paschoud, C
    Grannavel, C
    Pellikka, R
    Delaloye, AB
    JOURNAL OF NUCLEAR MEDICINE, 2004, 45 (10) : 1784 - 1790
  • [30] Phase 1/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy
    Illidge, Tim M.
    Bayne, Mike
    Brown, Nicholas S.
    Chilton, Samantha
    Cragg, Mark S.
    Glennie, Martin J.
    Du, Yong
    Lewington, Valerie
    Smart, James
    Thom, James
    Zivanovic, Maureen
    Johnson, Peter W. M.
    BLOOD, 2009, 113 (07) : 1412 - 1421
12345